one power player
within drug suppli chain
updat forecast estim dec
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research dec
estim dec
price data jan
rate updat jan
currenc amount express
valuat growth profit
methodolog valu compani
play critic
pharmaceut suppli chain decad come
perspect firm stand premier player believ
possess wide econom moat thank coloss scale
key cogs within pharmaceut
industri mani supply-chain particip depend
upon servic streamlin product distribut
procur anticip robust growth pharmaceut
industri long term provid firm
solid platform continu success
one three
distributor main supplier larg pharmaci outlet
walgreen express script mail order pharmaci firm
highli integr strateg agreement walgreen
suppli retail pharmaci drug inventori includ
gener last aspect key -- suppli higher-margin gener
drug one biggest gener drug retail outlet major
posit profit capit effici invest capit return
cours fiscal firm manag
excel job major contract integr exceed
initi growth profit expect walgreen
partnership believ reflect strong scale leverag
effici gain new highli integr
addit opportun
procur gener inventori alreadi coloss walgreen
boot allianc develop dynam enabl drug
distributor obtain gener inventori lower cost level
firm also major specialti drug distributor
posit favor benefit fastest-grow drug
categori within pharmaceut market
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
one three major pharmaceut distributor
 highli effici distribut asset firm activ includ
forecast logist servic firm also wholesal leader within
high-growth specialti distribut nich
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit dec
fair valu estim amerisourc
account firm recent acquisit smith
midtier drug distributor solid growth firm
walgreen partnership slight mix shift toward
done excel job drive organ revenu growth
ramp complex walgreen partnership
great effici firm also posit well
within fast-grow specialti drug distribut sector
largest distributor within market
factor drive solid gross dollar growth extend
addit solid revenu growth also anticip
increas capital-manag effici distributor
next sever year result increas
volum -- notabl integr walgreen
partnership amerisourc procur gener drug
suppli walgreen boot allianc develop
partnership obtain gener drug inventori lower
contribut outlook amerisourc confluenc
age popul influx previous uninsur
peopl healthcar market greater use
pharmaceut front-lin treatment provid
platform solid top- bottom-lin growth accordingli
factor five-year revenu compound-annual-growth-rate
averag oper margin explicit forecast
scenario analysi take consider effect
price volatil supplier price pressur pharmaceut
market growth ultim outcom walgreen
partnership bull-cas scenario factor
less price transpar higher profit result
also assum abl exert even
negoti leverag given access
addit factor high-single-digit industri growth
uptak drug usag increas faster initi
expect scenario fair valu estim
increas approxim per share
bear case assum effort bring price
addit assum gener sourc partnership
walgreen advantag
addit discount obtain also assum secular
industri growth driver fail materi par
current expect scenario fair valu
estim decreas per share
moat perspect three major pharmaceut
distributor carv wide econom moat
coloss size unmatch effici give key
critic role among manufactur retail outlet
solidifi long-term outsiz return accord
estim total retail pharmaceut spend
 littl billion major
spend flow oper major three
pharmaceut distributor domin result
robust sustain econom profit player
estim cardin health
combin market share well
combin dynam slim industri profit keep new
entrant bay new player would tough time
carv enough share effici leverag
distribut asset posit econom profit
dynam solidifi long-term competit posit
major three drug distributor firm also obtain
deep price discount drug manufactur mani
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
healthcar coverag
increas spend
pharmaceut product provid excel long-term
tailwind firm addit amerisourc play
critic role pharmaceut industri main
sourc drug suppli signific portion retail
pharmaci outlet effici distributor drug
custom acquir dynam
player essenti cogs along
critic massiv distribut oper
amerisourc mean enjoy excel asset effici
unparallel logist expertis driven decent
asset return howev abil effect manag
capit base true driver outsiz return drug
distributor firm produc top-tier asset turn cash
convers inventori manag metric
led outsiz roic -- trend believ last
despit recent drug price volatil associ
headlin risk believ amerisourc stabl
econom moat trend perspect recent
price headwind near-term firm abl
overcom obstacl given entrench posit
within global pharmaceut space demograph
trend skew older expans government-sponsor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
major pharmaceut
distributor billion annual revenu
size make firm prefer partner among
major drug manufactur mani retail pharmaci
opharmaceut spend continu grow
robustli next decad given demograph
shift expans medic insur
coverag current uninsur
specialti drug spend continu increas
believ distributor opportun captur
valu nich market improv top-
bottom-lin result
oprofit margin razor-thin
make signific price pressur major
effort procur cheaper suppli gener
product partner
walgreen enhanc negoti power
fixed-cost scale partnership fail outlook
futur revenu profit growth take hit
osal volum could take materi hit
feder govern implement scaled-back
healthcar legisl price control
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
amerisourc good financi health
continu prudent capit alloc polici
strong free cash product oper keep
amerisourc solid financi situat long term
main risk face push
greater government control drug price repeal
afford act concert push
mani pharmaceut stakehold institut
govern control drug price scenario
drug distributor could face prospect government-dict
profit addit current legitim
push within congress repeal key provis
certain mandat scale back drug wholesal
would like see lower volum moder headwind
respect posit scale dynam
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
believ stewardship
larg value-cr sharehold oper
execut capit manag benefici
econom profit firm signific distribut
gener sourc partnership agreement walgreen
part agreement enabl
acquir approxim equiti
balanc believ manag made right
strateg move agreement make amerisourcebergen
exclus drug supplier one world largest
retail pharmaci agreement also give
distributor access advantag gener drug
price firm also servic express script mail-ord
contract contract yield lower level
profit roic gain scale effici
econom posit past sever year
manag built amerisourcebergen
powerhous within specialti drug nich dynam
posit firm highli favor competit posit
within fast-grow specialti pharmaceut market
repres date owner name posit common share held report holder issuer
govern pension fund norway global
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
report solid quarter ramp rite aid
amerisourc report solid quarter firm seem
recov price pressur past year
reformul distribut network build
effici address increas pharmaceut volum
assum come year result
line expect reiter
fair valu estim wide-moat rate firm
although believ near-term result posit
believ posit long-term fundament
pharmaceut servic space robust buoy
amerisourc next sever year firm also play
critic role pharmaceut industri mani suppli
chain particip depend servic streamlin
product distribut procur believ
combin factor lead outsiz econom
profit next sever decad amerisourc
manag also state current process
invest new distribut facil complet
reorgan announc earlier year
effect bifurc compani
two major
oper pharmaceut drug sourc divis
consult anim health divis believ
realign posit bring relat
servic product two prong leadership
perspect realign benefici
long term streamlin structur help unlock
intern synergi give custom easier time
partner firm multipl product and/or
servic also believ enhanc effici
core drug busi allow maxim return
volum recent gain expans
walgreen contract addit rite aid volum
uncertainti chang price headwind domin
amerisourc report result guidanc fiscal third
quarter reflect highli uncertain tough oper
environ drug wholesal near-term issu
squeez amerisourc overal profit buy-sid
sell-sid issu creat vise product portfolio
quarterli result reflect pressur near-term
oper environ confid firm thrive
long term amerisourc remain critic link
within pharmaceut suppli chain distribut
relationship
integr client relationship posit advantag
variabl also lead wide econom moat
amerisourc reiter fair valu
estim given current stock sell-off believ
firm equiti give investor opportun qualiti
compani signific discount
manag team detail reorgan
announc june effect bifurc compani
two major oper pharmaceut drug
sourc divis consult anim health
divis believ realign posit
bring relat servic product two prong
leadership perspect realign
benefici long-term streamlin structur help
unlock intern synergi give custom easier time
partner firm multipl product and/or
amerisourc gross margin took hit quarter
fall basi point believ firm still
manag cite client contract renew
execut unfavor rate major sourc issu
dynam fall line price requir pbm
demand pharmaci order
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
includ restrict pharmaci network mani
pharmaci discount respect gener
inventori maintain grow posit within pbm
network creat domino effect
pharmaci seek cheaper price
respect wholesal expect trend abat
come year like continu pressur
near-term oper environ amerisourc
manag also maintain expect gener drug
price fall averag brand price
increas averag fiscal
metric well inflat rate firm
experienc last year price
dynam near-term issu major sourc
perspect
pharmaceut manufactur price strategi
influenc mani factor price experi
period rel high inflat deflat stagnat
thu believ import investor consid metric
mean-revert natur assess long-term
econom influenc thu long-term extrapol
near-term price gyrat creat excel valu
invest opportun major three drug
pharmaceut distribut space face sever
signific headwind past year addit
three major player stumbl specif
contract reformul loss expens relat
contract ramp pressur respect oper
howev essenti role firm play along
pharmaceut suppli chain chang
respect wide econom moat remain intact thu
believ major drug distributor thrive long
polit realiti much gop healthcar overhaul
mix impact healthcar coverag jul
polit realiti scale back healthcar coverag
million constitu much senat
gop overcom pass major overhaul
afford act loss two ye
vote initi revis senat republican plan
senat major leadership unabl push measur
would appeal moder
libertarian wing caucu thu believ
probabl substant repeal replac plan
becom law extrem low balanc find
develop posit manag care
hospit sector volum increas due expand
coverag remain place end
spectrum elimin variou fee tax
pharmaceut devic compani tabl
even though develop maintain statu quo
oper environ take away potenti
posit financi impact firm
believ senat take step toward
shore weak public exchang marketplac order
near term like requir meaning
level bipartisan negoti chamber congress
despit rhetor let marketplac fail
believ polit unten republican
allow scenario playout given control everi
branch feder govern signific
percentag affect vote district either republican
tossup lean addit believ congression
gop leadership keen move polit
minefield healthcar legisl toward initi
major overhaul tax code
bottom line believ like remain place
time come domin affect upon
healthcare-rel firm continu howev also
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
believ need legisl address long-
term issu concern relat certain aspect
law chiefli lawmak formul long-term
plan stabil public exchange/individu market
compris approxim quarter privat
insur space order keep premium cost check
prevent death-spir scenario develop
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end septemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
